ERBB2 and breast cancer: Enobosarm (GTx-024), one of the new SARM, has shown promising results in the case of an extensively pretreated woman with metastatic ER+/PR+/HER2–BC with high AR co-expression who reached partial radiographic response after four cycles of treatment with enobosarm (69).